P/16/2011

Key facts

Invented name
Nevanac
Active substance
nepafenac
Therapeutic area
Ophthalmology
Decision number
P/16/2011
PIP number
P/16/2011
Pharmaceutical form(s)
  • Eye drops
  • suspension
Condition(s) / indication(s)
Prevention of post operative pain and inflammation associated with cataract surgery
Route(s) of administration
Ocular use
Contact for public enquiries
Alcon Laboratories (UK) Ltd.
Doug.MacHatton@AlconLabs.com
United States
Phone: +1 8175518974
Fax: +1 8176154607
Decision type
W: decision granting a waiver in all age groups for all conditions/indications

Decision

How useful was this page?

Add your rating